Immutep LtdASX: IMM

INSIGHT-003 investigator-initiated trial - 1st patient dosed

· Issued by Immutep Ltd

Filed with ASX · · 2 pages · English

SYDNEY, AUSTRALIA–5 August 2021–Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003. This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus

Immutep Ltd on 6ix

Earlier from Immutep

Later from Immutep

All Immutep news releases